期刊文献+

口服川芎制剂预防对比剂肾病的疗效和安全性 被引量:7

The efficacy and safety of oral preparation of rhizoma chuanxiong for the prevention of contrastinduced nephropathy
下载PDF
导出
摘要 目的探讨上海长海医院自制川芎口服制剂头痛灵口服液在冠脉介入治疗中预防对比剂肾病(CIN)的疗效及安全性。方法将2014年4月—6月住院行择期冠脉介入的患者随机分为川芎组(113例)和对照组(109例),两组均常规水化治疗,川芎组在水化基础上加用川芎口服制剂头痛灵口服液,比较两组术后CIN的发生及川芎相关药物不良反应的情况。结果冠脉介入术后发生CIN者川芎组有5例(4.42%),对照组有13例(11.9%),两组间差异有统计学意义(χ2=4.191,P<0.05)。川芎组患者均未出现川芎相关的药物不良反应。发生CIN的18例患者在水化、碱化尿液治疗后均获恢复。结论在水化治疗基础上口服川芎制剂对冠脉介入术后CIN的发生有明显预防作用,且无明显不良反应。 Objective To evaluate the safety and efficacy of oral Changhai Hospital self-made preparation of rhizoma chuanxiong in preventing contrast-induced nephropathy(CIN) in patients undergoing selective percutaneous coronary intervention(PCI). Methods During the period from April 2014 to June31, 2014, a total of 222 patients with cardiac disorders were admitted to Changhai Hospital to receive selective coronary intervention. The patients were randomly divided into the study group(n = 113) and the control group(n = 109). Routine hydration therapy with 0.9% sodium chloride solution was performed in the patients of both groups, and additional oral preparation of rhizoma chuanxiong and oral liquid of headache pill were given to the patients of the study group. The incidences of CIN were compared between the two groups, and the chuanxiong-related side effects were analyzed. Results The incidence of CIN occurring after PCI in the study group and the control group was 4.42%(n = 5) and 11.9%(n = 13) respectively, and the difference between the two groups was statistically significant(χ2= 4.191, P 0.05). No chuanxiong-related side effects occurred. After hydration therapy and urine alkalization treatment all the 18 patients with CIN returned to normal status. Conclusion On the basis of hydration therapy, oral preparation of rhizoma chuanxiong can effectively prevent postoperative CIN from happening in patients undergoing selective percutaneous coronary intervention. Besides, oral preparation of rhizoma chuanxiong has no obvious side effects.
出处 《介入放射学杂志》 CSCD 北大核心 2015年第2期102-105,共4页 Journal of Interventional Radiology
关键词 冠脉介入 对比剂肾病 川芎 口服制剂 percutaneous coronary intervention contrast-induced nephropathy rhizoma chuanxiong oral preparation
  • 相关文献

参考文献14

  • 1Capodanno D, Ministeri M, Cumbo S, et al. Volume to creatinine clearance ratio in patients undergoing coronary angiography with or without percutaneous coronary intervention: implications of varying definitions of contrast induced nephropathy[J]. Catheter Cardiovasc Interv, 2014, 83: 907 912.
  • 2Abe M, Morimoto T, Akao M, et al. Relation of contrast induced nephropathy to long term mortality after percutaneous coronary intervention[J]. Am J Cardiol, 2014, 114: 362 368.
  • 3潘静薇,陆志刚,张佳胤,宣昶有,祁晟,汪年松,魏盟.冠状动脉介入治疗后迟发型对比剂肾病[J].介入放射学杂志,2013,22(1):15-19. 被引量:8
  • 4刘福颂,王伟.造影剂过敏致死亡6例分析[J].中国医药导报,2010,7(13):180-180. 被引量:13
  • 5Kalaiselvan V, Sharma S, Singh GN. Adverse reactions to contrast media: an analysis of spontaneous reports in the database of the pharmacovigilance programme of India[J]. Drug Saf, 2014, 37: 703 710.
  • 6池菊芳,郭航远,彭放,杨彪.经皮冠状动脉介入治疗术后长期联合阿司匹林和氯吡格雷抗血小板治疗的安全性评价[J].中国全科医学,2008,11(14):1254-1256. 被引量:8
  • 7Golshahi J, Nasri H, Gharipour M. Contrast induced nephropathy; A literature review[J]. J Nephropathol, 2014. 3: 51 56.
  • 8Burgess WP, Walker PJ. Mechanisms of contrast induced nephropathy reduction for saline (NaCl) and Sodium bicarbonate(NaHCO3)[J]. Biomed Res Int, 2014: 510385.
  • 9Ivanes F, Isorni MA, Halimi JM, et al. Predictive factors of contrast induced nephropathy in patients undergoing primary coronary angioplasty[J]. Arch Cardiovasc Dis, 2014, 107: 424 432.
  • 10Yang K, Liu W, Ren W, et al. Different interventions in preventing contrast induced nephropathy after percutaneous coronary intervention[J]. Int Urol Nephrol, 2014, 46: 1801 1807.

二级参考文献53

共引文献291

同被引文献89

引证文献7

二级引证文献77

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部